Soligenix, Inc. (LON:0A6I)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 10.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.56M |
| Shares Out | n/a |
| EPS (ttm) | -2.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,737 |
| Average Volume | 43,581 |
| Open | 1.800 |
| Previous Close | 1.790 |
| Day's Range | 1.611 - 1.800 |
| 52-Week Range | 1.105 - 6.200 |
| Beta | n/a |
| RSI | 43.22 |
| Earnings Date | Nov 10, 2025 |
About Soligenix
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflam... [Read more]
Financial Performance
In 2024, Soligenix's revenue was $119,371, a decrease of -85.78% compared to the previous year's $839,359. Losses were -$8.27 million, 34.6% more than in 2023.
Financial numbers in USD Financial StatementsNews
Soligenix (SNGX) Advances Phase 3 CTCL Study with Positive Safety Review
Soligenix (SNGX) Advances Phase 3 CTCL Study with Positive Safety Review
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J. , Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or th...
Insider Buying: Christopher Schaber Acquires Shares of Soligenix Inc (SNGX)
Insider Buying: Christopher Schaber Acquires Shares of Soligenix Inc (SNGX)
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J. , Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company...
Soligenix Announces Closing of $7.5 Million Public Offering
Cash runway extended through 2026 to fund multiple expected key inflection points PRINCETON, N.J. , Sept. 29, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a la...
Soligenix (SNGX) Launches Public Offering to Raise $7.5 Million
Soligenix (SNGX) Launches Public Offering to Raise $7.5 Million
Soligenix Prices 7.5 Mln Public Offering At $1.35/shr; Stock Up In Pre-market
(RTTNews) - Soligenix, Inc. (SNGX), a late-stage biopharmaceutical company, on Friday priced a public offering with the purchase and sale of 5,555,560 shares of stock and warrants to purchase up to 5,...
Soligenix stock down after pricing $7.5M public offering to raise capital
Soligenix Announces Pricing of $7.5 Million Public Offering
PRINCETON, N.J. , Sept. 26, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing product...
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J. , Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopha...
Soligenix files to sell 2.91M shares of common stock, 2.91M warrants
Get the latest on Soligenix’s 2.91M share and warrant sale. Learn how this financial move could impact investors.
Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
Two Year Stability demonstrated in both bivalent and trivalent configurations at temperatures of 40°C / 104°F PRINCETON, N.J. , Sept. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix ...
Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
PRINCETON, N.J. , Sept. 2, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Why Is Soligenix Stock Soaring On Monday?
Soligenix shares surge after FDA granted ... Full story available on Benzinga.com
Why Is Soligenix Stock Soaring On Monday?
Soligenix, Inc. SNGX stock is higher on Monday after the U.S. Food and Drug Administration granted orphan drug designation to dusquetide, the active ingredient in SGX945, for Behçet's Disease.
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
Provides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopha...
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
Provides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopha...
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
PRINCETON, N.J. , Aug. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer
AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeuti...
Crude Oil Falls 1%; Meta Earnings Top Views
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded down 0.15% to 44,393.57 while the NASDAQ rose 0.62% to 21,260.82. Th...
Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 1% on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 44,566.33 while the NASDAQ rose 1....
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease
Study results support advancing SGX945 in this difficult to treat orphan disease PRINCETON, N.J. , July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stag...
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease
Study results support advancing SGX945 in this difficult to treat orphan disease PRINCETON, N.J. , July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage...
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
PRINCETON, N.J. , July 8, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
Active Ingredient Manufacturing Transfer to the U.S. Complete PRINCETON, N.J. , July 1, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical ...